This research report provides a comprehensive analysis of the Plasma Protease C1-inhibitor Treatment market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Plasma Protease C1-inhibitor Treatment market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Plasma Protease C1-inhibitor Treatment, challenges faced by the industry, and potential opportunities for market players.
The global Plasma Protease C1-inhibitor Treatment market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Plasma Protease C1-inhibitor Treatment market presents opportunities for various stakeholders, including Hospital Pharmacies, Independent Pharmacies and Outlets. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Plasma Protease C1-inhibitor Treatment market. Additionally, the growing consumer demand present avenues for market expansion.
The global Plasma Protease C1-inhibitor Treatment market was valued at US$ 2070.2 million in 2023 and is projected to reach US$ 3300.8 million by 2030, at a CAGR of 6.9% during the forecast period.
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
Key Features:
The research report on the Plasma Protease C1-inhibitor Treatment market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Plasma Protease C1-inhibitor Treatment market.
Market Overview: The report provides a comprehensive overview of the Plasma Protease C1-inhibitor Treatment market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., C1-inhibitors, Kallikrein Inhibitor (Kalbitor)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Plasma Protease C1-inhibitor Treatment market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Plasma Protease C1-inhibitor Treatment market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Plasma Protease C1-inhibitor Treatment market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Plasma Protease C1-inhibitor Treatment market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Plasma Protease C1-inhibitor Treatment market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Plasma Protease C1-inhibitor Treatment market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Plasma Protease C1-inhibitor Treatment, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Plasma Protease C1-inhibitor Treatment market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Plasma Protease C1-inhibitor Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- C1-inhibitors
- Kallikrein Inhibitor (Kalbitor)
- Market segment by Application
- Hospital Pharmacies
- Independent Pharmacies and Outlets
Global Plasma Protease C1-inhibitor Treatment Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Takeda
- CSL
- Sanquin
- Pharming Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Plasma Protease C1-inhibitor Treatment, market overview.
Chapter 2: Global Plasma Protease C1-inhibitor Treatment market size in revenue.
Chapter 3: Detailed analysis of Plasma Protease C1-inhibitor Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments
by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments
by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Plasma Protease C1-inhibitor Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Plasma Protease C1-inhibitor Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Plasma Protease C1-inhibitor Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Plasma Protease C1-inhibitor Treatment Overall Market Size
2.1 Global Plasma Protease C1-inhibitor Treatment Market Size: 2023 VS 2030
2.2 Global Plasma Protease C1-inhibitor Treatment Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Plasma Protease C1-inhibitor Treatment Players in Global Market
3.2 Top Global Plasma Protease C1-inhibitor Treatment Companies Ranked by Revenue
3.3 Global Plasma Protease C1-inhibitor Treatment Revenue by Companies
3.4 Top 3 and Top 5 Plasma Protease C1-inhibitor Treatment Companies in Global Market, by Revenue in 2023
3.5 Global Companies Plasma Protease C1-inhibitor Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Plasma Protease C1-inhibitor Treatment Players in Global Market
3.6.1 List of Global Tier 1 Plasma Protease C1-inhibitor Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Plasma Protease C1-inhibitor Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Plasma Protease C1-inhibitor Treatment Market Size Markets, 2023 & 2030
4.1.2 C1-inhibitors
4.1.3 Kallikrein Inhibitor (Kalbitor)
4.2 By Type - Global Plasma Protease C1-inhibitor Treatment Revenue & Forecasts
4.2.1 By Type - Global Plasma Protease C1-inhibitor Treatment Revenue, 2019-2024
4.2.2 By Type - Global Plasma Protease C1-inhibitor Treatment Revenue, 2025-2030
4.2.3 By Type - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Plasma Protease C1-inhibitor Treatment Market Size, 2023 & 2030
5.1.2 Hospital Pharmacies
5.1.3 Independent Pharmacies and Outlets
5.2 By Application - Global Plasma Protease C1-inhibitor Treatment Revenue & Forecasts
5.2.1 By Application - Global Plasma Protease C1-inhibitor Treatment Revenue, 2019-2024
5.2.2 By Application - Global Plasma Protease C1-inhibitor Treatment Revenue, 2025-2030
5.2.3 By Application - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Plasma Protease C1-inhibitor Treatment Market Size, 2023 & 2030
6.2 By Region - Global Plasma Protease C1-inhibitor Treatment Revenue & Forecasts
6.2.1 By Region - Global Plasma Protease C1-inhibitor Treatment Revenue, 2019-2024
6.2.2 By Region - Global Plasma Protease C1-inhibitor Treatment Revenue, 2025-2030
6.2.3 By Region - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030
6.3.2 US Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.3.3 Canada Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.3.4 Mexico Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030
6.4.2 Germany Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.3 France Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.4 U.K. Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.5 Italy Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.6 Russia Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.7 Nordic Countries Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.4.8 Benelux Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030
6.5.2 China Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.5.3 Japan Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.5.4 South Korea Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.5.5 Southeast Asia Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.5.6 India Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030
6.6.2 Brazil Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.6.3 Argentina Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030
6.7.2 Turkey Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.7.3 Israel Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.7.4 Saudi Arabia Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
6.7.5 UAE Plasma Protease C1-inhibitor Treatment Market Size, 2019-2030
7 Plasma Protease C1-inhibitor Treatment Companies Profiles
7.1 Takeda
7.1.1 Takeda Company Summary
7.1.2 Takeda Business Overview
7.1.3 Takeda Plasma Protease C1-inhibitor Treatment Major Product Offerings
7.1.4 Takeda Plasma Protease C1-inhibitor Treatment Revenue in Global Market (2019-2024)
7.1.5 Takeda Key News & Latest Developments
7.2 CSL
7.2.1 CSL Company Summary
7.2.2 CSL Business Overview
7.2.3 CSL Plasma Protease C1-inhibitor Treatment Major Product Offerings
7.2.4 CSL Plasma Protease C1-inhibitor Treatment Revenue in Global Market (2019-2024)
7.2.5 CSL Key News & Latest Developments
7.3 Sanquin
7.3.1 Sanquin Company Summary
7.3.2 Sanquin Business Overview
7.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Major Product Offerings
7.3.4 Sanquin Plasma Protease C1-inhibitor Treatment Revenue in Global Market (2019-2024)
7.3.5 Sanquin Key News & Latest Developments
7.4 Pharming Group
7.4.1 Pharming Group Company Summary
7.4.2 Pharming Group Business Overview
7.4.3 Pharming Group Plasma Protease C1-inhibitor Treatment Major Product Offerings
7.4.4 Pharming Group Plasma Protease C1-inhibitor Treatment Revenue in Global Market (2019-2024)
7.4.5 Pharming Group Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Plasma Protease C1-inhibitor Treatment Market Opportunities & Trends in Global Market
Table 2. Plasma Protease C1-inhibitor Treatment Market Drivers in Global Market
Table 3. Plasma Protease C1-inhibitor Treatment Market Restraints in Global Market
Table 4. Key Players of Plasma Protease C1-inhibitor Treatment in Global Market
Table 5. Top Plasma Protease C1-inhibitor Treatment Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Plasma Protease C1-inhibitor Treatment Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Plasma Protease C1-inhibitor Treatment Revenue Share by Companies, 2019-2024
Table 8. Global Companies Plasma Protease C1-inhibitor Treatment Product Type
Table 9. List of Global Tier 1 Plasma Protease C1-inhibitor Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Plasma Protease C1-inhibitor Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Plasma Protease C1-inhibitor Treatment Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Plasma Protease C1-inhibitor Treatment Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Plasma Protease C1-inhibitor Treatment Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Plasma Protease C1-inhibitor Treatment Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2025-2030
Table 30. Takeda Company Summary
Table 31. Takeda Plasma Protease C1-inhibitor Treatment Product Offerings
Table 32. Takeda Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn) & (2019-2024)
Table 33. Takeda Key News & Latest Developments
Table 34. CSL Company Summary
Table 35. CSL Plasma Protease C1-inhibitor Treatment Product Offerings
Table 36. CSL Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn) & (2019-2024)
Table 37. CSL Key News & Latest Developments
Table 38. Sanquin Company Summary
Table 39. Sanquin Plasma Protease C1-inhibitor Treatment Product Offerings
Table 40. Sanquin Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn) & (2019-2024)
Table 41. Sanquin Key News & Latest Developments
Table 42. Pharming Group Company Summary
Table 43. Pharming Group Plasma Protease C1-inhibitor Treatment Product Offerings
Table 44. Pharming Group Plasma Protease C1-inhibitor Treatment Revenue (US$, Mn) & (2019-2024)
Table 45. Pharming Group Key News & Latest Developments
List of Figures
Figure 1. Plasma Protease C1-inhibitor Treatment Segment by Type in 2023
Figure 2. Plasma Protease C1-inhibitor Treatment Segment by Application in 2023
Figure 3. Global Plasma Protease C1-inhibitor Treatment Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Plasma Protease C1-inhibitor Treatment Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Plasma Protease C1-inhibitor Treatment Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Plasma Protease C1-inhibitor Treatment Revenue in 2023
Figure 8. By Type - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 9. By Application - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 10. By Type - Global Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 12. By Application - Global Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 14. By Region - Global Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 15. By Country - North America Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 16. US Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 20. Germany Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 21. France Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 28. China Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 32. India Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 34. Brazil Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Plasma Protease C1-inhibitor Treatment Revenue Market Share, 2019-2030
Figure 37. Turkey Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Plasma Protease C1-inhibitor Treatment Revenue, (US$, Mn), 2019-2030
Figure 41. Takeda Plasma Protease C1-inhibitor Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. CSL Plasma Protease C1-inhibitor Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Sanquin Plasma Protease C1-inhibitor Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Pharming Group Plasma Protease C1-inhibitor Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
